TQB 3454
Alternative Names: TQB-3454Latest Information Update: 29 Nov 2023
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
- Phase I Haematological malignancies; Solid tumours
Most Recent Events
- 29 Nov 2023 TQB 3454 is still in phase I trials for Haematological malignancies (First-line therapy, In adults, In the elderly, Late-stage disease) and Solid tumours (First-line therapy, In adults, In the elderly, Late-stage disease) in China (PO) (NCT04481607)
- 18 Nov 2023 Chia Tai Tianqing Pharmaceutical Group plans a phase I trial In volunteers in China (PO) in November 2023 (NCT06139367)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Haematological-malignancies (First-line therapy, In the elderly, Late-stage disease, In adults) in China (PO, Tablet)